Significant Insider Change: The Insider, Longitude Venture Partners L.P. Sold 36,941 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT)

November 26, 2016 - By whatsonthorold

Significant Insider Change: The Insider, Longitude Venture Partners L.P. Sold 36,941 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT)

Longitude Venture Partners L.P. Insider Buy

Corcept Therapeutics Inc’s insider Longitude Venture Partners L.P. sold 36,941 shares of the publicly listed company in sold with a broker dated 25/11/2016. The mentioned shares were sold at the average share price which was $9.3, for a total sell of $345,165. Currently, Longitude Venture Partners L.P., has in hand 13.96 million shares, which accounts for 12.71% of the Company’s market capitalization. The insider transaction was performed on 25-11-2016 and was made public in a Form 4 at the Security Exchange Commission’s website.

Insitutional Activity: The institutional sentiment increased to 2.23 in 2016 Q2. Its up 0.43, from 1.8 in 2016Q1. The ratio is positive, as 13 funds sold all Corcept Therapeutics Incorporated shares owned while 22 reduced positions. 24 funds bought stakes while 39 increased positions. They now own 45.31 million shares or 34.44% more from 33.70 million shares in 2016Q1.

Blackrock Japan Communication holds 0% or 1,274 shares in its portfolio. Deere accumulated 69,255 shares or 0.02% of the stock. The Kansas-based Creative Planning has invested 0% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Tfs Ltd Com reported 150,979 shares or 0.15% of all its holdings. Nationwide Fund Advsr holds 0% of its portfolio in Corcept Therapeutics Incorporated (NASDAQ:CORT) for 48,502 shares. Stevens Mgmt L P accumulated 0% or 17,323 shares. Moreover, Voya Invest Mngmt Lc has 0% invested in Corcept Therapeutics Incorporated (NASDAQ:CORT) for 28,453 shares. Credit Suisse Ag owns 83,622 shares or 0% of their US portfolio. State Bank Of Montreal Can accumulated 0% or 18,424 shares. D E Shaw And Inc has 108,433 shares for 0% of their US portfolio. Guggenheim Capital Lc has invested 0% of its portfolio in Corcept Therapeutics Incorporated (NASDAQ:CORT). Principal Gp accumulated 0% or 14,878 shares. Geode Mngmt has invested 0% of its portfolio in Corcept Therapeutics Incorporated (NASDAQ:CORT). Cambridge Trust has 40,000 shares for 0.02% of their US portfolio. Blackrock Inc last reported 0% of its portfolio in the stock.

Insider Transactions: Since November 7, 2016, the stock had 0 buys, and 8 sales for $24.01 million net activity. ENRIGHT PATRICK G sold $5.20 million worth of stock or 544,100 shares. 30,000 shares were sold by MAHONEY DAVID L, worth $280,500. 158,812 shares with value of $1.35M were sold by WILSON JAMES N on Wednesday, November 9. BELANOFF JOSEPH K sold $4.49M worth of stock or 500,000 shares. Another trade for 544,100 shares valued at $5.20M was made by Longitude Venture Partners L.P. on Thursday, November 17.

The stock decreased 1.18% or $0.11 during the last trading session, hitting $9.18. About 357,529 shares traded hands. Corcept Therapeutics Incorporated (NASDAQ:CORT) has risen 79.30% since April 25, 2016 and is uptrending. It has outperformed by 73.28% the S&P500.

Corcept Therapeutics Inc. is a pharmaceutical firm engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The company has a market cap of $1.05 billion. The Company’s focus is on those disorders that are associated with a steroid hormone cortisol. It has a 233.71 P/E ratio. Elevated levels and abnormal release patterns of cortisol have been implicated in a range of human disorders.

According to Zacks Investment Research, “Corcept Therapeutics Incorporated is a pharmaceutical company. It is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The company focuses on disorders that are associated with a steroid hormone called cortisol. It is developing its lead product, CORLUX for the treatment of the psychotic features of psychotic major depression. Corcept Therapeutics Incorporated is headquartered in Menlo Park, California.”

Analysts await Corcept Therapeutics Incorporated (NASDAQ:CORT) to report earnings on March, 7. They expect $0.03 earnings per share, up 50.00% or $0.01 from last year’s $0.02 per share. CORT’s profit will be $3.43M for 76.50 P/E if the $0.03 EPS becomes a reality. After $0.02 actual earnings per share reported by Corcept Therapeutics Incorporated for the previous quarter, Wall Street now forecasts 50.00% EPS growth.

More news for Corcept Therapeutics Incorporated (NASDAQ:CORT) were recently published by: Fool.com, which released: “Corcept Therapeutics Rose 18% in March. Here’s Why.” on April 06, 2016. Fool.com‘s article titled: “Why Corcept Therapeutics Incorporated Shares Were Mauled” and published on May 07, 2014 is yet another important article.

CORT Company Profile

Corcept Therapeutics Inc., incorporated on May 13, 1998, is a pharmaceutical firm engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company’s focus is on those disorders that are associated with a steroid hormone cortisol. Elevated levels and abnormal release patterns of cortisol have been implicated in a range of human disorders. The Firm is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). The Firm also has discovered approximately three structurally distinct series of selective cortisol modulators, all of which share mifepristone’s affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor, and so do not terminate pregnancy or cause other side effects associated with progesterone receptor antagonism. The Firm has begun pre-clinical and clinical development of its lead compounds from these series.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>